New targeted drug BL-M07D1 enters early human testing for Hard-to-Treat cancers

NCT ID NCT05461768

Recruiting now Disease control Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This early-phase trial is testing a new drug called BL-M07D1 in people with advanced HER2-positive or low-expression breast cancer and other solid tumors that have not responded to standard treatments. The study has two parts: first, finding the safest dose, and then testing that dose more closely. About 26 participants will be enrolled to check safety, side effects, and how the drug moves through the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: BL-M07D1 (a drug given by IV infusion that targets HER2-positive cancer cells)
What this could lead to: If it works, this could point toward a new treatment option for people with advanced HER2-positive or low-expression breast cancer and other solid tumors who have run out of standard options.
What could go wrong: This is a very early Phase 1 trial with only 26 participants, so safety and dosing are still being figured out. It may not work or could have side effects, and it will take years before it might be available.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm HER2 positive breast carcinoma neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER LOCALLY ADVANCED OR METASTATIC SOLID TUMOR

Contacts and locations

Locations

Dongguan People's Hospital
RECRUITING

Dongguan, Guangdong, China
Fujian Cancer Hospital
RECRUITING

Fuzhou, Fujian, China
Jinan Central Hospital
RECRUITING

Jinan, Shandong, China
Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine
RECRUITING

Hangzhou, Zhejiang, China
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
RECRUITING

Guangdong, Guangzhou, 510120, China
The First Affiliated Hospital of Zhengzhou University
RECRUITING

Zhengzhou, Henan, China
Zhongnan Hospital of Wuhan University
RECRUITING

Wuhan, Hubei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.